Abstract

Brain (BNP) and atrial natriuretic peptides (ANP) have been identified which may represent endogenous agonists of kidney receptor subtypes. Quantitative in vitro autoradiography was used to investigate the regional distribution of receptor subpopulations and the competitive inhibition of 125I porcine BNP1-26 (pBNP1-26) and 125I rat alpha-ANP1-28 (rANP1-28) renal binding sites. Specific, high affinity binding (Kd 0.2-1.37 nM range) was localized to glomeruli, inner medulla, interlobar and arcuate arteries, vasa recta bundles, and smooth muscle in the renal pelvis. pBNP1-26 competed for the same sites as rANP1-28 but displayed a lower potency and was less selective for nonclearance sites. Clearance binding sites were discriminated by competitive inhibition with C-ANP4-23 and comprised some 65% of glomerular sites as well as the vast majority of sites in the renal pelvis. Nonclearance sites predominated in the inner medulla and intrarenal arteries. C-terminal changes in amino acid sequence induced a significant loss of inhibitory potency. Immunohistochemical studies identified a distinct population of BNP-like immunoreactive renal nerve fibers, associated with intra-renal arteries. Circulating natriuretic peptides and BNP sequences derived from renal nerves may influence renal function by interacting with specific receptor subpopulations in the kidney.

Highlights

  • Brain (BNP) and atrial natriuretic peptides (ANP) and activity (3-6)

  • Clearance binding sites were discriminated by competitive inhibition with C-ANP4-23and comprised some 65%of glomerular sites as well as the vast majority of sites in the renal pelvis

  • Immu- The possibility of ANP receptors being coupled toother nohistochemicalstudies identified a distinct population secondary messenger systems cannot be excluded, of BNP-like immunoreactive renal nerve fibers, asso- as theinteraction of C-ANP4-2:wI ith ANP receptors has been ciated with intra-renal arteries

Read more

Summary

Introduction

Brain (BNP) and atrial natriuretic peptides (ANP) and activity (3-6). It is distinct from another guanylate cyhave been identified which may represent endogenous clase-linked, 115-kDa molecular mass, (B-ANP) receptor agonists of kidney receptor subtypes. Unlabeled pBNP1-26, rANP1-28,and urodilatin inhibited 12sI-pBNPl~26 bindinag to similar extent, with nosignificant difference being found between ICbo values forsites in glomeruli, inner medulla, and intra-renal arteries.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call